AAM All Access Podcast - Featuring AAM CEO Dan Leonard and leaders in the generics and biosimilars industry.

New Generics Are Less Available in Medicare Than Commercial Plans

AAM releases a new report confirming Medicare Part D plans continue to fail to get new generics to patients.

Read Report
AAM All Access Podcast with Dan Leonard

We're pleased to present the AAM All Access Podcast with our President and CEO Dan Leonard, bringing the story of today’s generics and biosimilars industry to life through the voices of its leaders and health care experts.

Learn More
What We Know—and What We Don’t

In the past two decades, misunderstood and exaggerated stats regarding the generics supply chain have been cited.

View #RxFacts
Take With Confidence

Generic Prescription Drugs: Your Health. Our Commitment.

Learn More
Patient Stories: Voices of Access

AAM's Voices of Access report features patients across the country who tell the impact of accessible generic and biosimilar medicines.

Meet the AAM Patients
Health Care Savings, State by State

The average state saved $6.1 billion from the use of generic drugs in 2019. How much did your state save?

Read Blog
Industry Response to COVID-19

The coronavirus (COVID-19) pandemic is disrupting everyday life around the world and imposing unprecedented stress on our health care system. Here are some responses and resources from the U.S. generics and biosimilars industry.

Learn More

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Policy

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Teamwork of business colleagues, consultation new strategy plan business and market growth on financial document graph report, conference to making growth profit

Jul 28, 2021 | Rachel Schwartz

Joanne Duncan Joins AAM as Chief Operating Officer

New Evidence Shows Medicare Part D Plans Continue to Fail to Get New Generics to Seniors

Jul 19, 2021 | Rachel Schwartz

AAM Releases New Report: New Generics Are Less Available in Medicare Than Commercial Plans

New Evidence Shows Medicare Part D Plans Continue to Fail to Get New Generics to Seniors

Jul 19, 2021 | Craig Burton

Seniors Are Still Missing Out on Savings in Medicare Part D

New Evidence Shows Medicare Part D Plans Continue to Fail to Get New Generics to Seniors

Jul 13, 2021 | Erica Klinger

New Evidence Shows Medicare Part D Plans Continue to Fail to Get New Generics to Seniors

AAM All Access Podcast

Jul 7, 2021 | Dan Leonard

Introducing the AAM All Access Podcast with Dan Leonard

AAM Patients - Voices of Access

Jul 6, 2021 | Erica Klinger

A New Resource Showcases Patient Stories. Are You Up Next?